AAM
CERE

Alpine Associates Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Alpine Associates Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,353,694
Closed -$96.2M – 57
2024
Q2 		$96.2M Buy
2,353,694
+12,300
+0.5% +$512K 4.6% 8
2024
Q1 		$99M Buy
2,341,394
+697,294
+42% +$29.3M 3.86% 10
2023
Q4 		$69.7M Buy
+1,644,100
New +$47.2M 3.57% 11

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Alpine Associates Management's CERE Position: Q3 2024 in Review

Alpine Associates Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 2,353,694 shares — an estimated $96.2M sold.

Alpine Associates Management first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $99M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Alpine Associates Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Alpine Associates Management sold 2,353,694 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $96.2M.
  • Alpine Associates Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Alpine Associates Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $99M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Alpine Associates Management's 13F filing for Q3 2024, filed 8 Nov 2024.